Telix Lifts Revenue 56% as It Doubles Down on Late-Stage Radiopharmaceutical Pipeline

Telix Pharmaceuticals ( (AU:TLX) ) has provided an update.

Telix reported FY 2025 revenue of US$803.8 million, a 56% increase that exceeded guidance, and generated positive adjusted operating cash flow while absorbing higher costs from acquisitions and expanded commercial infrastructure. The company invested heavily in R&D, particularly in late-stage therapeutics, and ended the year with US$141.9 million in cash after significant M&A outlays and completion of a contingent payment tied to Illuccix.

The precision medicine segment delivered 22% revenue growth on strong Illuccix volumes and the U.S. launch of Gozellix, with a 64% gross margin and higher segment EBITDA supporting further global launches. Telix also expanded its Telix Manufacturing Solutions network through RLS and other facilities, advanced multiple radiotherapeutic candidates into pivotal or early-phase trials, and moved key imaging assets, including Zircaix and Pixclara, toward U.S. and European approvals, underscoring a strategic shift from single-product reliance to an integrated global platform in radiopharmaceuticals.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$34.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals is an Australia-based biopharmaceutical company focused on radiopharmaceuticals and precision nuclear medicine for oncology. Its key commercial products include Illuccix for prostate cancer imaging and Gozellix, with a growing portfolio of diagnostic and therapeutic agents such as Zircaix and Pixclara targeting prostate, kidney and brain cancers through both imaging and targeted radionuclide therapies.

Average Trading Volume: 2,324,604

Technical Sentiment Signal: Sell

Current Market Cap: A$2.99B

Find detailed analytics on TLX stock on TipRanks’ Stock Analysis page.